Dr. Lyou on Sequencing Apalutamide in Prostate Cancer

Partner | Cancer Centers | <b>City of Hope</b>

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses optimal sequencing with apalutamide (Erleada) in prostate cancer.

In recent years, many options have become available for the first-line treatment of men with prostate cancer, says Lyou. However, these options have made treatment sequencing more challenging, Lyou explains.

Apalutamide is currently FDA approved to treat men with metastatic castration-sensitive prostate cancer (mCSPC), as well as nonmetastatic castration-resistant prostate cancer (mCRPC), says Lyou. As such, using apalutamide as frontline treatment for patients with castration-sensitive disease leaves the greatest number of treatment options available for patients who progress to metastatic castration-resistant prostate cancer (mCRPC), says Lyou. In mCRPC, apalutamide is not FDA approved and treatment options include docetaxel, abiraterone acetate (Zytiga) plus prednisone, or enzalutamide (Xtandi), concludes Lyou.